Concerning therapeutic options, current data on secukinumab does not support its superiority over anti-TNF after previous TNF-inhibitor treatment.26,27 This suggests that despite therapeutic advances in spondyloarthritis, patients are still experiencing multiple switches due to lack of efficacy. Here, TNF is linked to spondyloarthropathy.